Eclipta alba (L.) Hassk is used traditionally in diabetes mellitus in India and the plant extract is reported to possess anti-diabetic activity. A bioactivity-guided isolation approach based on α-glucosidase inhibition was used to identify the constituents contributing towards the inhibition of the enzyme and probably contributing towards its anti-diabetic activity. Four echinocystic acid glycosides were thus isolated, of which eclalbasaponin VI, isolated from the n-butanol fraction, was found to be the most potent (IC 50 54.2 ± 1.3 µM). The compound is an uncompetitive type of inhibitor with Ki 26.1 µM. A quantitative estimation of the constituents was established using RP-HPLC.
Eclipta alba (L.) Hassk (syn. Eclipta prostrata; Family: Asteraceae) is an important plant used traditionally in diabetic complications [1a] . Beside the traditional uses there are several scientific contributions on the biological activities shown by the plant extract and isolated constituents [1b-d,2a] . A bio-assay guided approach has been used in the present investigation to identify the constituents responsible for α-glucosidase inhibition. The yeast αglucosidase inhibition technique, employed for the screening of αglucosidase inhibitors from plant and food stuffs [2b], has been adopted in this study.
Based on the inhibition of enzyme α-glucosidase, the methanolic extract (ME; IC 50 2.08 ± 0.12mg/mL) was fractionated into three fractions. The ethyl acetate (EAF) and n-butanol fractions (NBF) showed inhibition of the enzyme (Table 1) , while the aqueous fraction was inactive. Purification of both the ethyl acetate and n-butanol fractions led to the isolation of two echinocystic acid glycosides, identified as eclalbasaponin I and eclalbasaponin II, from the ethyl acetate fraction, and of two other echinocystic acid glycosides, identified as eclalbasaponin III and VI, from the n-butanol fraction ( Figure 1A ). The isolated constituents were characterized using mass spectrometric, 1 H NMR and 13 C NMR spectroscopic analysis, and by comparison with literature data [3,4a] .
The four isolated saponins demonstrated concentration dependent inhibition of the enzyme ranging from moderate to potent (Table 1) . Eclalbasaponin VI was found to be the most potent with an IC 50 of 54.2 ± 1.3 µM, while other constituents demonstrated moderate inhibition of the enzyme. This finding suggests that the point of attachment and the number of sugars affect the enzyme activity, but the inhibitory potential was highest for eclalbasaponin VI carrying a -SO 3 H group. Since eclalbasaponin VI displayed the most potent inhibition, kinetics were studied in its absence and presence at different substrate concentrations ( Figure 1B) . The double reciprocal Lineweaver-Burk plot displayed parallel linear lines showing a decrease in Vmax and Km with increasing concentration of the compound. The data suggested that eclalbasaponin VI is an A quantitative estimation of the constituents in the methanolic extract and fractions was performed using RP-HPLC. The chromatogram for the methanolic extract and fractions displayed four distinct peaks ( Figure S1 ). Table 2 demonstrates the amount of constituents present in the extract and fractions.The present study reveals that the saponins isolated from E. alba possess significant αglucosidase inhibitory activity and that eclalbasaponin VI is the most potent. Eclalbasaponin VI was isolated from the n-butanol fraction, which demonstrated better inhibition of the enzyme than the ethyl acetate fraction, and this is also suggested by the HPLC analyses. The present investigation is the first report on the possible use of the isolated constituents (echinocystic acid glycosides) as α-glucosidase inhibitors and is in agreement with the previous study reporting the anti-hyperglycemic activity of the extract [1b]. Experimental Plant material: The whole plant, collected in August-2010 from the locality of Kolkata (India), was identified at the Botanical Gardens, Howrah (India), and a specimen is deposited in the institute herbarium for future reference (NIP-K/BCP/003).
Extraction and isolation of α-glucosidase inhibitory constituents:
The shed-dried plant material (2 kg) was extracted with methanol at room temperature for 48 h. The extract was filtered and then evaporated under reduced pressure at 45 o C. This step was executed 4 times to afford the crude methanolic extract (215 g), part of which (200 g) was suspended in water and fractionated successively with ethyl acetate and n-butanol. The extracts were evaporated under reduced pressure and lyophilized to give residues of the ethyl acetate (43.99 g), n-butanol (31.63 g) and aqueous fractions (124.38 g). The ethyl acetate fraction (40 g) was subjected to CC over a bed of silica gel (100-200 mesh size, Merck India) and separated with a chloroform: methanol gradient into 5 fractions (Fr 1 to 5). Fraction 4 was further subjected to silica gel CC and eluted with a chloroform:methanol gradient (100:1 to 1:1 v/v) to give 9 fractions (Fr 4-1 to 4-9). Further silica gel CC of fraction 4-7 led to the isolation of 2 glycosides, which were purified by semi-preparative HPLC using methanol:water (60:40 v/v) as mobile phase at a flow rate of 2.5 mL/min; the eluates were monitored at 210 nm. The major peaks corresponding to both the constituents were collected and evaporated under reduced pressure to give eclalbasaponin I (27 mg) and eclalbasaponin II (117 mg).The n-butanol fraction (30 g) was chromatographed on silica gel using increasing polarity of different solvents to obtain, in order, FR-1 (light petroleum), FR-2 (light petroleum / chloroform, 1:1 v/v), FR-3 (chloroform), FR-4 (chloroform / methanol, 90:10 v/v), FR-5 (chloroform / methanol, 80:20 v/v), FR-6 (chloroform / methanol, 70:30 v/v), FR-7 (chloroform / methanol, 60:40 v/v), and FR-8 (chloroform / methanol, 50:50 v/v). Repeated silica gel CC of FR-6 followed by purification by HPLC, led to the isolation of eclalbasaponin III (83 mg) and eclalbasaponin VI (40 mg).
α-Glucosidase inhibition assay:
The enzyme inhibitory assay was performed as described earlier [4d] . Briefly 25 µL of extract/constituent solution at different concentrations, in 0.1 M phosphate buffer (pH-6.8), was mixed with 25 µL of enzyme solution containing 0.5 U/mL in 0.1 M phosphate buffer (pH-6.8).
The mixed solution was incubated at 37 ± 1 o C for 10 min to allow inhibition of the enzyme by the extract or compound under test. After incubation, 25 µL of the substrate, p-nitrophenyl α-Dglucopyranoside, 0.5 mM solution in 0.1 M phosphate buffer (pH-6.8), was added to the above mixture and incubated at 37±1 o C for 30 min. Then the reaction was terminated by the addition of 100 µL of 0.2 M sodium carbonate solution. The absorbance of the solution containing p-nitrophenol was measured at 405 nm. The uninhibited enzyme was taken as control and an appropriate blank was used for all the samples. An appropriate DMSO control was used whenever required and the final concentration of DMSO was maintained below 2% v/v, which was found not to affect the enzyme activity. Acarbose was used as a standard inhibitor of the enzyme. The assay was performed in triplicate and in 3 independent experiments.
Quantitative analysis by HPLC-DAD:
HPLC analyses were performed at 25 ± 1 o C using sample solutions filtered through 0.45 µm membrane (Whatman syringe filter) and analyzed (20 µL injected volume) using a Shimadzu (Japan) system equipped with SCL-10A VP Shimadzu system controller, SPD-M10A VP Shimadzu diode array detector, LC-10AT VP Shimadzu liquid chromatography pump, Class VP software, and a Rheodyne injector with 20 μL loop. Separation was achieved using a Water's XTerra TM RP C18 column, 4.6 x 250 mm, 5 µm particle size; isocratic elution was achieved using the mobile phase methanol:water (60:40 v/v) at a flow rate of 1 mL/min. The eluate was monitored at 210 nm. Quantitative estimation of the constituents present in the methanolic extract and fractions was done using the calibration curve of the standard solution (Microsoft Office Excel 2007). The standard solutions of extract and fractions (10 mg/mL) and compounds (1 mg/mL) were prepared in methanol.
